Valeria Faccenda

Medical Physicist at Fondazione IRCCS San Gerardo dei Tintori Monza (Italy)

[ESTRO @ESTRO_RT]

⏳ Deadline 1 June! Help map CBCT imaging practices across Europe for the #OPTIMIZE-RT project.
Calling all European #RTTs, #MedPhys, #Oncologists & #QualityManagers.
👉 Join here: https://t.co/VAMXf5LnrT
#Radiotherapy #Radonc #PatientSafety

[Valeria Faccenda @valefacc22]

@piet_ost @alison_tree @ESTRO_RT @CZamboglou @DrAndrewLoblaw @royalmarsdenNHS @VedangMurthy Very interesting points raised by "opponents" and well-balanced debate 😊👏🏻 Technology pushes boundaries, while standard equipment remains valid and accessible. Either way, all PCa patients can receive SBRT treatments ☢️💪🏻

[Alison Tree 💙 @alison_tree]

Great debate @ESTRO_RT - do we need augmented/adaptive radiotherapy for prostate cancer? @CZamboglou @DrAndrewLoblaw @valefacc22 and Adam
Mitchell @royalmarsdenNHS Good points made by both sides, but if we can do better, surely we should?

[Valeria Faccenda @valefacc22]

First ESTRO missed since Madrid 2021…a lot of FOMO, but I’ll still be there in thoughts and somehow also in face 😊 Don’t miss tomorrow debate on augmented SBRT for prostate cancer, which I was honored to contribute to 🌰 Can’t wait to follow the discussion!

#ESTRO26 #PCa #GU

[Valeria Faccenda @valefacc22]

🧠 Fusion uncertainty is real...even “perfect” expert fusions can differ.
Quantifying operator variability is key to define a probabilistic GS and benchmarking automatic registration vs human performance 🧮

@EFOMP_org @fisica_medica #SRS #automatism

👉🏻https://t.co/Mt4vELVqPh

[Stefano Arcangeli @StAr_MCM74]

🔍Check out a post-hoc analysis of the ABRUPT trial on the 🔗between ☢️ RT dose to pelvic substructures & late GU TOX

⛔️ bladder trigone D1cc ≥20.3 Gy
⛔️ NVB D0.035 cc ≥23.6 Gy

➡️https://t.co/HiDlJqyj3s

#prostatecancer @OncoAlert @oncodaily @urotoday

[Stefano Arcangeli @StAr_MCM74]

🙏 Huge credit to all speakers, moderators and colleagues who made the 1️⃣#prostateSBRTMonza 🇮🇹Symposium a great success🤩

#ProstateCancer
@ESTRO_RT @ISRSy
@airo_young

[Valeria Faccenda @valefacc22]

🚀 Join us for the 1st symposium on prostate SBRT. Medical physicists are welcome too!

📅 5–6 February 2026
📍 Hotel de la Ville, Monza
🔗 https://t.co/HR65qm2Dva

Don’t miss this chance to learn and discuss with experts in the field.

@ESTRO_RT @ISRSy @fisica_medica @AIRO

[Federica Ferrario @Fefe_Ferrario]

🧨 Join us for #PCa #SBRT Symposium by @StAr_MCM74 & @PanizzaDenis with 🔝tier international faculty @piet_ost @CDraulans @CZamboglou and 🌟Italian RadOncs together with @ESTRO_RT President @BarbaraJereczek

🔗Registrations open—limited seats
https://t.co/icoFJ27mw5

@valefacc22

[Federica Ferrario @Fefe_Ferrario]

AIRO 2025 couldn’t have been better!
🔹 Presented the #POPART data (again 🤭)
🔹 Elected Board Member & Secretary of the GU Study Group
🔹 Awarded the AIRO Young Scholarship for an ESTRO School

Feeling grateful, inspired and ready for the next steps 🚀
#AIRO2025 #RadOnc

[Stefano Arcangeli @StAr_MCM74]

💥 #AIRO2025: 3 days of updates in cutting-edge treatments… yet the best one is still us❗️💪🏻

#radonc
@unimib @AIROyoung

[Shankar Siva @_ShankarSiva]

📢 NRGGU005 Phase III: 698 pts with intermediate-risk #ProstateCancer RCT; SBRT (n=353) vs M-IMRT (n=345)
✅ SBRT → better bowel HRQOL (MCID 35% vs 44%, p=0.03)
⚖️No diff in urinary HRQOL; EPIC continence favours SBRT
❌futile for DFS; IMRT had ⬇️3-yr biochemical failure (4.2% vs 7.8%)
SBRT safe, better QoL, ⁉️but not superior for DFS #ASTRO25 #RadOnc #PCSM

[Daniel E Spratt @DrSpratticus]

#astro25

@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.

Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased

3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.

Goodbye WPRT

[Stefano Arcangeli @StAr_MCM74]

What a great honor and privilege to deliver 2️⃣ oral presentations at #ASTRO25
Special 🙏 to @Fefe_Ferrario @valefacc22 @riccardo_ray @panizza @CiroFranzese1

#prostatecancer
#abrupt
#popart

@urotoday @oncodaily
@airo_young

[Valeria Faccenda @valefacc22]

@StAr_MCM74 @Fefe_Ferrario @riccardo_ray @Panizza @CiroFranzese1 @urotoday @oncodaily @airo_young 👏🏻👏🏻👏🏻 huge satisfaction!! 🎊

[Drew Moghanaki @DrewMoghanaki]

🇨🇦 Single-fraction lung SBRT results from British Columbia further support this as a great treatment option for stage I NSCLC. #ASTRO25 https://t.co/JjCMsKutKH

[Shankar Siva @_ShankarSiva]

🚫 In >2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms).
🔹 PC-specific survival 98%
🔹 Slight ↓ in biochemical failure with WPRT
🔹 More grade 2 GI adverse events
⁉️how to reconcile with POP-RT trial in PSMA era? Lower risk cohort? #ASTRO25 #RadOnc

[Shankar Siva @_ShankarSiva]

🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

[Valeria Faccenda @valefacc22]

🇩🇪🍺💙

[Giulia Marvaso @GiuliaMarvaso84]

💙✨ Girl Power, Radiotherapy & a touch of #Oktoberfest spirit in #Munich 🍻
Fighting #ProstateCancer with science, smiles & resilience! 🎗️ #RadiationOncology #WomenInScience

[Stefano Arcangeli @StAr_MCM74]

📢“One Voice for Radiotherapy”
One voice to champion access, awareness, and appreciation of the vital role radiotherapy plays in cancer care❗️

#OneVoiceForRadiotherapy
#WRAD
#WorldRTDay
@ESTRO_RT @ASTRO_org @AIROyoung @airo_young

[Valeria Faccenda @valefacc22]

🚨When you squeeze your intrafraction motion data and end up changing the margins to 4 mm iso!

Didn’t even remember writing this paper back at the end of last year… but just in time for some pleasant holiday reading, you can finally check it out ⤵️⤵️⤵️

[Denis Panizza @PanizzaDenis]

How tight can SBRT prostate margins go?
⏱ ≤8 min → 4–5 mm = safe
⚠️ 2–3 mm = real-time tracking mandatory

Our analysis on 192 prostate SBRT fractions and 2 motion monitoring systems is finally out.

https://t.co/up5CwdLBoP

@aapmHQ @EFOMP_org @ASTRO_org @ESTRO_RT @oncodaily